Hillrom (NYSE: HRC) today announced it has reached a definitive agreement to acquire Bardy Diagnostics, Inc. (BardyDx), an innovator in digital health and a leading provider of ambulatory cardiac monitoring technologies. Under the terms of the agreement, Hillrom will purchase BardyDx …
Trending at Lumira Ventures
Lumira co-leads $12.8 Million raise in Cyrano Therapeutics
Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy for smell and flavor restoration, has raised $12.8 million in a Series A financing led by Remiges Ventures and Lumira Ventures, with the participation of additional investors. …
enGene Receives Fast Track Designation for EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer
enGene Inc., A biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to enGene for EG-70, the company’s lead …
Antios Therapeutics Appoints Gregory T. Mayes Chief Executive Officer
Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors Mayes to lead continued development of ATI-2173 as a potential backbone of a curative regimen for Hepatitis B (“HBV”) ATLANTA, Dec. 01, 2020 …
Corvia Medical Completes Randomization In REDUCE LAP-HF II Pivotal Trial And Gains FDA Authorization To Provide Continued Access For The Corvia Atrial Shunt
TEWKSBURY, Mass., Nov. 17, 2020 /PRNewswire/ — Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), today announced completion of randomization in its REDUCE LAP-HF II global, pivotal trial. The trial is evaluating the Corvia® Atrial Shunt (IASD®) …
AmacaThera’s Co-founder and CSO Dr. Molly Shoichet receives Canada’s most prestigious honour for breakthroughs in regenerative medicine.
OTTAWA, ON, Nov. 10, 2020 /CNW/ – The world is shining the spotlight on science now more than ever as we face the challenges of the COVID-19 pandemic. As Canadian science and engineering researchers continue to lead on the world …
Satsuma ASCEND trial results expected to support STS101 NDA filing in Q4 2021
Analysis of results from EMERGE™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021 Cash, cash equivalents and marketable securities of $82.1 million as of September 30, 2020; based on current operating plans, expected …
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis NEW YORK & MONTREAL– Bristol Myers Squibb (NYSE: BMY) and Forbius, a privately held, clinical-stage protein engineering company that designs and develops …
AmacaThera to commence Phase 1 clinical trial for non-opioid, post-operative pain management.
TORONTO, Oct. 20, 2020 /PRNewswire – AmacaThera Inc. is pleased to announce approval from Health Canada to proceed to a Phase 1 clinical trial with its lead asset, a long-acting anesthetic formulation for the treatment of post-surgical pain. “This huge …
Canada’s Edesa Biotech in Frontlines of COVID-19 Treatment Race.
As COVID-19 continues its destructive path as the most formidable global pandemic in a century, pharmaceutical companies around the globe are racing to develop drug treatments to mitigate the damage. Edesa Biotech, Inc., headquartered in Markham, Ont., is on the …
HistoSonics Appoints Dr. Joe Amaral to Position of Vice President of Medical Affairs.
MINNEAPOLIS, Sept. 9, 2020 /PRNewswire/ — HistoSonics, developer of the non-invasive Edison platform and novel sonic beam therapy, announced today the appointment of Joe Amaral, MD, to the newly created position of Vice President of Medical Affairs, where he will oversee global clinical development …
Bardy Diagnostics® Announces Appointment of Kevin Hykes as President and Chief Executive Officer
SEATTLE, Sept. 8, 2020 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading developer and provider of remote ambulatory cardiac monitoring and digital health solutions, announced today the appointment of Kevin Hykes as President and Chief Executive Officer, effective August 31, 2020. Hykes will …
Antios Therapeutics Announces Publication Describing Preclinical Profile of ATI-2173
ATLANTA, Sept. 1, 2020 /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, announced today the publication of preclinical results of ATI-2173, Antios’ lead oral drug candidate for …
enGene Receives Funding Through Cystic Fibrosis Foundation’s Path to a Cure for the Discovery of Novel Gene Therapies to Treat Cystic Fibrosis
OSTON and MONTRÉAL, Oct. 29, 2020 /PRNewswire/ -enGene Inc., a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today an award from the Cystic Fibrosis Foundation for the discovery of genetic medicines to treat patients …
G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer
– PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration– Priority Review for trilaciclib is based on positive data from three randomized clinical trials showing robust myelopreservation benefits– G1 launching expanded access program (EAP) for …